Herold Advisors Inc. Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Herold Advisors Inc. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,400 shares of the medical research company’s stock after selling 200 shares during the quarter. Herold Advisors Inc.’s holdings in IQVIA were worth $1,249,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of IQV. AdvisorNet Financial Inc grew its stake in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after purchasing an additional 95 shares during the period. BKM Wealth Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at approximately $32,000. Activest Wealth Management purchased a new position in shares of IQVIA during the 4th quarter worth approximately $35,000. CVA Family Office LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $43,000. Finally, CoreFirst Bank & Trust acquired a new stake in shares of IQVIA in the 3rd quarter valued at $44,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,285 shares of company stock worth $10,331,003. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on IQV. Robert W. Baird lifted their price target on shares of IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Truist Financial raised their price objective on shares of IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. SVB Leerink began coverage on shares of IQVIA in a research report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, UBS Group lifted their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

IQVIA Stock Up 0.4 %

Shares of NYSE IQV opened at $234.88 on Friday. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The firm has a 50-day moving average price of $245.28 and a 200 day moving average price of $223.02. The stock has a market capitalization of $42.63 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 2.26 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.54 earnings per share. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.